Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
暂无分享，去创建一个
Andre H Crepaldi | M. Dimopoulos | A. Jakubowiak | Sung-Soo Yoon | G. Iosava | J. San-Miguel | J. Bladé | M. Qi | C. Doyen | A. Liberati | S. Knop | M. Mateos | T. Shelekhova | M. Cavo | Kenshi Suzuki | J. Ukropec | Z. Nagy | M. Garg | Jianping Wang | Maria I Krevvata | T. Fujisaki | L. Pour | S. Grosicki | R. Kobos | M. Cook | M. Krevvata | A. Crepaldi | P. Campbell | Ying Chen | P. Lúcio | S. Wroblewski | Anupa Kudva | S. Yoon